Home › Diffuse Large B-Cell Lymphoma › NCT04502394
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Cohort 1: Confirmed diagnosis of TP53wt DLBCL (WHO); R/R DLBCL after at least 2 prior lines of treatment or 1 prior for patients who are ineligible for stem cell transplant * Cohort 2: Confirmed diagnosis of TP53wt CLL (iwCLL); R/R CLL after at least 1 prior line of treatment * ECOG 0 to 2 * Adequate hematologic, hepatic, and renal functions. Exclusion Criteria: * Prior treatment with any MDM2 inhibitor * Prior treatment with any BTK inhibitor
About the study
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, combined with acalabrutinib for the treatment of adults with Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia. Participants must be relapsed/refractory (having failed prior therapy)
What is being tested
- KRT-232 (drug)
- acalabrutinib (drug)
Sponsor: Kartos Therapeutics, Inc. · Participants: 84 · Started: Feb 23, 2021
Contact the study team
- John Mei · Phone: 650-542-0136
- Michael Yee · Phone: 650-839-7361
Official record on ClinicalTrials.gov — NCT04502394
Locations in the U.S.
| Indiana | Goshen Center for Cancer Care, Goshen |
| Ohio | University of Cincinnati, Cincinnati The Ohio State University Comprehensive Cancer Center, Columbus |
| Texas | UT Southwestern Medical Center, Dallas |
Conditions
From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.